Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02131129 · ClinicalTrials.gov registry record · NA

rTMS in First Episode Psychosis

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT02131129: Completed NA study, sponsored by Indiana University.

NCT02131129 is a NA study that has completed, run by Indiana University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02131129, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the development of social and vocational impairment that is associated with cognitive dysfunction in schizophrenia. This study will also seek to refine the understanding of the brain circuitry that mediates the potential pro-cognitive effects of rTMS through the use of functional magnetic resonance imaging (fMRI) at baseline and following the course of rTMS administration.

Primary Outcome

rTMS effectiveness in improving cognitive performance as measured by the Brief Assessment of Cognition in Schizophrenia (BACS) composite score. The BACS is a battery specifically designed to measure treatment-related changes in cognition, and has alternate forms, thus minimizing practice effects. The battery includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed, and generates a composite score that is calculated by summing t-s

Interventions

  • DEVICE Sham Comparator
  • DEVICE rTMS

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-04-30
Est. Completion 2016-12
Phase NA
Indiana University

890 total trials

What the finished NCT02131129 record still lists

NCT02131129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.

NCT02131129 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02131129 about?

NCT02131129 is a clinical study titled "rTMS in First Episode Psychosis". This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the development of social and vocational impairment that is associated with cognit...

What is the current status of trial NCT02131129?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-04-30. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02131129?

The interventions under investigation include: Sham Comparator (DEVICE), rTMS (DEVICE).

Who is sponsoring clinical trial NCT02131129?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02131129's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02131129, the US trial registry maintained by the National Library of Medicine. NCT02131129 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.